Pharmacological and alimentary alteration of the gastric barrier

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 6, 2014, Pages 981-994

  Boltin, Doron ^a,b   Niv, Yaron ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Atrophic gastritis; Helicobacter pylori; MUC; Mucin; Mucosal defence; Non steroidal anti inflammatory drugs; Nutrient; Proton pump inhibitor

Indexed keywords

ALCOHOL; ANTIOXIDANT; BICARBONATE; CAFFEINE; FLUORIDE; INTESTINAL TREFOIL FACTOR; MINERAL; MUCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEPSINOGEN; PROTON PUMP INHIBITOR; VITAMIN; PEPSIN A;

ADVERSE OUTCOME; AGE RELATED GASTROPATHY; AGING; ARTICLE; ATROPHIC GASTRITIS; CENTRAL NERVOUS SYSTEM FUNCTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFECT; GASTRIC BARRIER; GASTRITIS; GASTROINTESTINAL MUCOSA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HORMONAL REGULATION; HUMAN; IDIOPATHIC DISEASE; INTESTINE EPITHELIUM; LONG TERM CARE; MUCOSAL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL HYPERTENSIVE GASTROPATHY; STOMACH ACID; STOMACH ACID SECRETION; STOMACH DISEASE; STOMACH MUCOSA; STOMACH ULCER; STRESS; STRESS RELATED MUCOSAL DISEASE; VASODILATATION; ANIMAL; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; SECRETION (PROCESS);

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTRIC ACID; GASTRIC MUCOSA; GASTRITIS; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HUMANS; PEPSIN A; PROTON PUMP INHIBITORS;

EID: 84925224213     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.09.001     Document Type: Review

References (91)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231: 232-5.
2. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric campylobacter. Med J Aust 1985;142: 436-9.
3. Johansson M, Synnerstad I, Holm L. Acid transport through channels in the mucous layer of rat stomach. Gastroenterology 2000;119: 1297-304.
4. Rossmann H, Bachmann O, Wang Z, Shull GE, Obermaier B, Stuart-Tilley A, et al. Differential expression and regulation of AE2 anion exchanger subtypes in rabbit parietal and mucous cells. J Physiol Lond 2001;534: 837-48.
5. Niv Y, Fraser GM. The alkaline tide phenomenon. J Clin Gastroenterol 2002;35: 5-8.
6. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: Protection against acid and pepsin. Am J Physiol Cell Physiol 2005;288: C1-19.
7. Niv Y, Hardy B, Koren R, Rodiomov G, Fraser GM. Association between gastric acid and mucin secretion in dyspeptic patients. Digestion 2002;65: 141-8.
8. Richter C, Tanaka T, Yada RY. Mechanism of activation of the gastric aspartic proteinases: Pepsinogen, progastricsin and prochymosin. Biochem J 1998;335(Pt 3): 481-90.
9. Agréus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47: 136-47.
10. Telaranta-Keerie A, Kara R, Paloheimo L, Härkönen M, Sipponen P. Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: An observational study among 4256 volunteers without specific complaints. Scand J Gastroenterol 2010;45: 1036-41.
11. Ho SB, Roberton AM, Shekels LL, Lyftogt CT, Niehans GA, Toribara NW. Expression cloning of gastric mucin complementary DNA and localization of mucin gene expression. Gastroenterology 1995;109: 735-47.
12. Ho SB, Takamura K, Anway R, Shekels LL, Toribara NW, Ota H. The adherent gastric mucous layer is composed of alternating layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci 2004;49: 1598-606.
13. Boltin D, Halpern M, Levi Z, Vilkin A, Morgenstern S, Ho SB, et al. Gastric mucin expression in H. pylori-related, nonsteroidal anti-inflammatory drug-related and idiopathic ulcers. World J Gastroenterol 2012;18: 4597-603.
14. Kinoshita K, Taupin DR, Itoh H, Podolsky DK. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: Structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 2000;20: 4680-90.
15. Thim L, Madsen F, Poulsen SS. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 2002; 32: 519-27.
16. Svanes K, Ito S, Takeuchi K, Silen W. Restitution of the surface epithelium of the in vitro frog gastric mucosa after damage with hyperosmolar sodium chloride. Morphologic and physiologic characteristics. Gastroenterology 1982;82: 1409-26.
17. Nguyen T, Chai J, Li A, Akahoshi T, Tanigawa T, Tarnawski AS. Novel roles of local insulin-like growth factor-1 activation in gastric ulcer healing: Promotes actin polymerization, cell proliferation, re-epithelialization, and induces cyclooxygenase-2 in a phosphatidylinositol 3-kinase-dependent manner. Am J Pathol 2007;170: 1219-28.
18. Suemasu S, Tanaka K, Namba T, Ishihara T, Katsu T, Fujimoto M, et al. A role for HSP70 in protecting against indomethacininduced gastric lesions. J Biol Chem 2009;284: 19705-15.
19. Tanaka K, Tsutsumi S, Arai Y, Hoshino T, Suzuki K, Takaki E, et al. Genetic evidence for a protective role of heat shock factor 1 against irritant-induced gastric lesions. Mol Pharmacol 2007;71: 985-93.
20. Bauer B,Wex T, Kuester D, Meyer T, Malfertheiner P. Differential expression of human b defensin 2 and 3 in gastric mucosa of H. pylori-infected individuals. Helicobacter 2013;18: 6-12.
21. Peskar BM. Neural aspects of prostaglandin involvement in gastric mucosal defense. J Physiol Pharmacol 2001;52: 555-68.
22. Kaneko H, Taché Y, Kusugami K. Importance of medullary thyrotropin-releasing hormone in brain-gut circuits regulating gastric integrity: Preclinical studies. J Gastroenterol 2002;37(Suppl. 14): 128-32.
23. Chatzaki E, Lambropoulou M, Constantinidis TC, Papadopoulos N, Tache Y, Minopoulos G, et al. Corticotropin-releasing factor (CRF) receptor type 2 in the human stomach: Protective biological role by inhibition of apoptosis. J Cell Physiol 2006;209: 905-11.
24. Brzozowski T, Konturek PC, Drozdowicz D, Konturek SJ, Pawlik M, Sliwowski Z, et al. Role of central and peripheral ghrelin in the mechanism of gastric mucosal defence. Inflammopharmacology 2005;13: 45-62.
25. Filaretova LP, Filaretov AA, Makara GB. Corticosterone increase inhibits stress-induced gastric erosions in rats. Am J Physiol 1998;274: G1024-30.
26. Filaretova L, Bagaeva T, Podvigina T, Makara G. Various ulcerogenic stimuli are potentiated by glucocorticoid deficiency in rats. J Physiol Paris 2001;95: 59-65.
27. Filaretova L, Podvigina T, Bagaeva T, Morozova O. From gastroprotective to ulcerogenic effects of glucocorticoids: Role of long-term glucocorticoid action. Curr Pharm Des 2014;20: 1045-50.
28. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008;134: 1842-60.
29. Saha A, Hammond CE, Beeson C, Peek RM, Smolka AJ. Helicobacter pylori represses proton pump expression and inhibits acid secretion in human gastric mucosa. Gut 2010;59: 874-81.
30. Schepp W, Dehne K, Herrmuth H, Pfeffer K, Prinz C. Identification and functional importance of IL-1 receptors on rat parietal cells. Am J Physiol 1998;275: 1094-105.
31. Wiedemann T, Hofbaur S, Tegtmeyer N, Huber S, Sewald N, Wessler S, et al. Helicobacter pylori CagL dependent induction of gastrin expression via a novel alpha-beta5-integrin-integrin linked kinase signalling complex. Gut 2012;61: 986-96.
32. Celli JP, Turner BS, Afdhal NH, Keates S, Ghiran I, Kelly CP, et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A 2009;106: 14321-6.
33. Van de Bovenkamp Jeroen HB, Mahdavi J, Korteland-Van Male Anita M, Buller HA, Einerhand AlexandraWC, Boren T, et al. The MUC5AC glycoprotein is the primary receptor for Helicobacter pylori in the human stomach. Helicobacter 2003;8: 521-32.
34. Tanaka S, Mizuno M, Maga T, Yoshinaga F, Tomoda J, Nasu J, et al. H. pylori decreases gastric mucin synthesis via inhibition of galactosyltransferase. Hepatogastroenterology 2003;50: 1739-42.
35. Peterson AJ, Menheniott TR, O'Connor L, Walduck AK, Fox JG, Kawakami K, et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology 2010;139: 2005-17.
36. Kawakubo M, Ito Y, Okimura Y, Kobayashi M, Sakura K, Kasama S, et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004;305: 1003-6.
37. McGuckin MA, Linden SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011;9: 265-78.
38. Lindén S, Semino-Mora C, Liu H, Rick J, Dubois A. Role of mucin Lewis status in resistance to Helicobacter pylori infection in pediatric patients. Helicobacter 2010;15: 251-8.
39. Nakayama M, Kimura M, Wada A, Yahiro K, Ogushi K, Niidome T, et al. Helicobacter pylori VacA activates the p38/activating transcription factor 2-mediated signal pathway in AZ-521 cells. J Biol Chem 2004;279: 7024-8.
40. D'Elios MM, Bergman MP, Azzurri A, Amedei A, Benagiano M, De Pont JJ, et al. H(+),K(+)-atpase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology 2001;120: 377-86.
41. van Driel Ian R, Baxter AG, Laurie KL, Zwar TD, Gruta La, Nicole L, et al. Immunopathogenesis, loss of T cell tolerance and genetics of autoimmune gastritis. Autoimmun Rev 2002;1: 290-7.
42. Cunliffe RN. Alpha-defensins in the gastrointestinal tract. Mol Immunol 2003;40: 463-7.
43. Peura DA. Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med 1985;103: 173.
44. Leung FW, Itoh M, Hirabayashi K, Guth PH. Role of blood flow in gastric and duodenal mucosal injury in the rat. Gastroenterology 1985;88: 281-9.
45. Yasue N, Guth PH. Role of exogenous acid and retransfusion in hemorrhagic shock-induced gastric lesions in the rat. Gastroenterology 1988;94: 1135-43.
46. Jia Y,WeiW, Ma B, Xu Y, LiuW,Wang Y, et al. Activation of p38 MAPK by reactive oxygen species is essential in a rat model of stress-induced gastric mucosal injury. J Immunol 2007;179: 7808-19.
47. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol 1999;128: 1659-66.
48. Kobata A, Kotani T, Komatsu Y, Amagase K, Kato S, Takeuchi K. Dual action of nitric oxide in the pathogenesis of ischemia/reperfusion-induced mucosal injury in mouse stomach. Digestion 2007;75: 188-97.
49. Tarnawski A, Pai R, Deng X, Ahluwalia A, Khomenko T, Tanigawa T, et al. Aging gastropathy-novel mechanisms: Hypoxia, up-regulation of multifunctional phosphatase PTEN, and proapoptotic factors. Gastroenterology 2007;133: 1938-47.
50. Gronbech JE, Lacy ER. Role of gastric blood flow in impaired defense and repair of aged rat stomachs. Am J Physiol 1995; 269: G737-44.
51. Tarnawski AS, Sarfeh IJ, Stachura J, Hajduczek A, Bui HX, Dabros W, et al. Microvascular abnormalities of the portal hypertensive gastric mucosa. Hepatology 1988;8: 1488-94.
52. Tomikawa M, Akiba Y, Kaunitz JD, Kawanaka H, Sugimachi K, Sarfeh IJ, et al. New insights into impairment of mucosal defense in portal hypertensive gastric mucosa. J Gastrointest Surg 2000;4: 458-63.
53. Kawanaka H, Jones MK, Szabo IL, Baatar D, Pai R, Tsugawa K, et al. Activation of eNOS in rat portal hypertensive gastric mucosa is mediated by TNF-alpha via the PI 3-kinase-AKT signaling pathway. Hepatology 2002;35: 393-402.
54. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6: 489-504.
55. Tanaka A, Araki H, Hase S, Komoike Y, Takeuchi K. Up-regulation of COX-2 by inhibition of COX-1 in the rat: A key to NSAIDinduced gastric injury. Aliment Pharmacol Ther 2002;16(Suppl. 2): 90-101.
56. Filaretova L, Tanaka A, Komoike Y, Takeuchi K. Selective cyclooxygenase-2 inhibitor induces gastric mucosal damage in adrenalectomized rats. Inflammopharmacology 2002;10: 413-22.
57. Wallace JL, McKnightW, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119: 706-14.
58. Takeeda M, Yamato M, Kato S, Takeuchi K. Cyclooxygenase isozymes involved in adaptive functional responses in rat stomach after barrier disruption. J Pharmacol Exp Ther 2003;307: 713-9.
59. Husain SS, Szabo IL, Pai R, Soreghan B, Jones MK, Tarnawski AS. MAPK (ERK2) kinaseea key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sci 2001;69: 3045-54.
60. Bias P, Buchner A, Klesser B, Laufer S. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: Results from a randomized, controlled trial. Am J Gastroenterol 2004;99: 611-8.
61. Spicer Z, Miller ML, Andringa A, Riddle TM, Duffy JJ, Doetschman T, et al. Stomachs of mice lacking the gastric H,K-ATPase alpha-subunit have achlorhydria, abnormal parietal cells, and ciliated metaplasia. J Biol Chem 2000;275: 21555-65.
62. Driman DK, Wright C, Tougas G, Riddell RH. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 1996;41: 2039-47.
63. Kakei N, Ichinose M, Tatematsu M, Shimizu M, Oka M, Yahagi N, et al. Effects of long-term omeprazole treatment on adult rat gastric mucosaeenhancement of the epithelial cell proliferation and suppression of its differentiation. Biochem Biophys Res Commun 1995;214: 861-8.
64. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986;35(Suppl. 1): 42-55.
65. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993;7(Suppl. 1): 41-50. discussion 61-6.
66. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334: 1018-22.
67. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118: 661-9.
68. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon Anthony TR, Bazzoli F, et al. Management of Helicobacter pylori infectionethe maastricht IV/Florence consensus report. Gut 2012;61: 646-64.
69. den Elzen WPJ, Groeneveld Y, RuijterWde, Souverijn JHM, Le Cessie S, AssendelftWJJ, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008;27: 491-7.
70. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57: 422-8.
71. Broeren Maarten AC, Geerdink Engelien AM, Vader HL, van den Wall Bake AWarmold L. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009;151: 755-6.
72. Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998;12: 83-98.
73. Niv Y, Boltin D, Halpern M, Cohen M, Levi Z, Vilkin A, et al. Mucin side chain sugar residues expression in Helicobacter pylori, NSAID, and idiopathic peptic ulcers. Gastroenterology 2012;142: S-493.
74. Niv Y, Boltin D. Secreted and membrane-bound mucins and idiopathic peptic ulcer disease. Digestion 2012;86: 258-63.
75. Pfeiffer A, Hogl B, Kaess H. Effect of ethanol and commonly ingested alcoholic beverages on gastric emptying and gastrointestinal transit. Clin Investig 1992;70: 487-91.
76. Wegener M, Schaffstein J, Dilger U, Coenen C, Wedmann B, Schmidt G. Gastrointestinal transit of solid-liquid meal in chronic alcoholics. Dig Dis Sci 1991;36: 917-23.
77. Singer MV, Leffmann C, Eysselein VE, Calden H, Goebell H. Action of ethanol and some alcoholic beverages on gastric acid secretion and release of gastrin in humans. Gastroenterology 1987;93: 1247-54.
78. Lenz HJ, Ferrari-Taylor J, Isenberg JI. Wine and five percent ethanol are potent stimulants of gastric acid secretion in humans. Gastroenterology 1983;85: 1082-7.
79. Teyssen S, Gonzalez-Calero G, Schimiczek M, Singer MV. Maleic acid and succinic acid in fermented alcoholic beverages are the stimulants of gastric acid secretion. J Clin Invest 1999;103: 707-13.
80. Murray LJ, Lane AJ, Harvey IM, Donovan JL, Nair P, Harvey RF. Inverse relationship between alcohol consumption and active Helicobacter pylori infection: The Bristol Helicobacter project. Am J Gastroenterol 2002;97: 2750-5.
81. Borger HW, Schafmayer A, Arnold R, Becker HD, Creutzfeldt W. The influence of coffee and caffeine on gastrin and acid secretion in man (author's transl). Dtsch Med Wochenschr 1976;101: 455-7.
82. Shimamoto T, Yamamichi N, Kodashima S, Takahashi Y, Fujishiro M, Oka M, et al. No association of coffee consumption with gastric ulcer, duodenal ulcer, reflux esophagitis, and non-erosive reflux disease: A cross-sectional study of 8013 healthy subjects in Japan. PLoS One 2013;8: E65996.
83. Cohen S, Booth Jr. GH. Gastric acid secretion and lower-esophageal-sphincter pressure in response to coffee and caffeine. N Engl J Med 1975;293: 897-9.
84. Rubach M, Lang R, Bytof G, Stiebitz H, Lantz I, Hofmann T, et al. A dark brown roast coffee blend is less effective at stimulating gastric acid secretion in healthy volunteers compared to a medium roast market blend. Mol Nutr Food Res 2014.
85. Kim M, Cho SY, Han S in, Koh SD, Perrino BA. CaM kinase II and phospholamban contribute to caffeine-induced relaxation of murine gastric fundus smooth muscle. Am J Physiol Cell Physiol 2005;288(6): C1202-10. http://dx.doi.org/10.1152/ajpcell.00299.2004.
86. Das TK, Susheela AK, Gupta IP, Dasarathy S, Tandon RK. Toxic effects of chronic fluoride ingestion on the upper gastrointestinal tract. J Clin Gastroenterol 1994;18: 194-9.
87. Spak CJ, Sjostedt S, Eleborg L, Veress B, Perbeck L, Ekstrand J. Tissue response of gastric mucosa after ingestion of fluoride. BMJ 1989;298: 1686-7.
88. Gupta IP, Das TK, Susheela AK, Dasarathy S, Tandon RK. Fluoride as a possible aetiological factor in non-ulcer dyspepsia. J Gastroenterol Hepatol 1992;7: 355-9.
89. Phull PS, Price AB, Thorniley MS, Green CJ, Jacyna MR. Vitamin E concentrations in the human stomach and duodenumecorrelation with Helicobacter pylori infection. Gut 1996;39: 31-5.
90. Sanderson MJ, White KL, Drake IM, Schorah CJ. Vitamin E and carotenoids in gastric biopsies: The relation to plasma concentrations in patients with and without Helicobacter pylori gastritis. Am J Clin Nutr 1997;65: 101-6.
91. Nair S, Norkus EP, Hertan H, Pitchumoni CS. Micronutrient antioxidants in gastric mucosa and serum in patients with gastritis and gastric ulcer: Does Helicobacter pylori infection affect the mucosal levels? J Clin Gastroenterol 2000;30: 381-5.